What supports this idea is the proliferation of publications, with no sign of abating, written by clinicians who describe an ever widening range of successful applications for products from the NovoSorb stable.
We’ve seen the language used shift from “novel” matrix to SOC in what has been a relatively short period of time.
And this has largely been clinician-led and based on clinical experience rather than laboratory testing.
You’re right, there’s no going back.
PNV Price at posting:
$1.30 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)